Citadel Advisors - SYROS PHARMACEUTICALS INC ownership

SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 95 filers reported holding SYROS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.46 and the average weighting 0.1%.

Quarter-by-quarter ownership
Citadel Advisors ownership history of SYROS PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2022$22,000
-87.9%
22,393
-85.4%
0.00%
Q1 2022$182,000
-43.5%
153,702
+55.8%
0.00%
Q4 2021$322,000
-57.3%
98,645
-41.5%
0.00%
Q3 2021$754,000
-44.4%
168,628
-32.2%
0.00%
Q2 2021$1,356,000
-78.7%
248,648
-70.7%
0.00%
-100.0%
Q1 2021$6,356,000
+177.4%
849,782
+302.4%
0.00%
Q4 2020$2,291,000
+1609.7%
211,177
+1579.3%
0.00%
Q2 2020$134,000
+1.5%
12,575
-47.1%
0.00%
Q4 2018$132,000
-29.0%
23,759
+30.5%
0.00%
Q2 2018$186,000
-80.9%
18,207
-72.5%
0.00%
-100.0%
Q3 2017$975,00066,2490.00%
Other shareholders
SYROS PHARMACEUTICALS INC shareholders Q1 2022
NameSharesValueWeighting ↓
Ally Bridge Group (NY) LLC 3,139,895$23,486,0004.50%
Samsara BioCapital, LLC 2,189,199$14,769,0002.72%
Bain Capital Life Sciences Investors, LLC 5,785,036$43,272,0002.45%
Omega Fund Management, LLC 1,562,500$11,688,0001.11%
Flagship Pioneering Inc. 2,938,494$21,980,0000.35%
EcoR1 Capital, LLC 1,000,000$7,480,0000.33%
Altium Capital Management LP 126,702$948,0000.26%
Nikko Asset Management Americas, Inc. 5,042,009$37,714,0000.18%
Artal Group S.A. 1,025,000$7,667,0000.14%
Orbimed Advisors 1,837,500$13,745,0000.13%
View complete list of SYROS PHARMACEUTICALS INC shareholders